- Home
- Search Results
- Page 1 of 1
Search for: All records
-
Total Resources2
- Resource Type
-
0001000001000000
- More
- Availability
-
20
- Author / Contributor
- Filter by Author / Creator
-
-
Chen, Weiqiang (1)
-
Chi, Andrew (1)
-
Chi, Andrew S (1)
-
Cui, Xin (1)
-
Delorenzo, Michael (1)
-
Frenster, Joshua (1)
-
Griggs, Christopher (1)
-
Jain, Rajan (1)
-
Kurz, Sylvia C (1)
-
Ma, Chao (1)
-
Morales, Renee-Tyler Tan (1)
-
Peng, Yansong (1)
-
Placantonakis, Dimitris G (1)
-
Qian, Weiyi (1)
-
Serrano, Jonathan (1)
-
Shen, Guomiao (1)
-
Snuderl, Matija (1)
-
Stanley, Natalie (1)
-
Sturton, Cynthia (1)
-
Sulman, Erik P (1)
-
- Filter by Editor
-
-
null (1)
-
& Spizer, S. M. (0)
-
& . Spizer, S. (0)
-
& Ahn, J. (0)
-
& Bateiha, S. (0)
-
& Bosch, N. (0)
-
& Brennan K. (0)
-
& Brennan, K. (0)
-
& Chen, B. (0)
-
& Chen, Bodong (0)
-
& Drown, S. (0)
-
& Ferretti, F. (0)
-
& Higgins, A. (0)
-
& J. Peters (0)
-
& Kali, Y. (0)
-
& Ruiz-Arias, P.M. (0)
-
& S. Spitzer (0)
-
& Sahin. I. (0)
-
& Spitzer, S. (0)
-
& Spitzer, S.M. (0)
-
-
Have feedback or suggestions for a way to improve these results?
!
Note: When clicking on a Digital Object Identifier (DOI) number, you will be taken to an external site maintained by the publisher.
Some full text articles may not yet be available without a charge during the embargo (administrative interval).
What is a DOI Number?
Some links on this page may take you to non-federal websites. Their policies may differ from this site.
-
null (Ed.)Programmed cell death protein-1 (PD-1) checkpoint immunotherapy efficacy remains unpredictable in glioblastoma (GBM) patients due to the genetic heterogeneity and immunosuppressive tumor microenvironments. Here, we report a microfluidics-based, patient-specific ‘GBM-on-a-Chip’ microphysiological system to dissect the heterogeneity of immunosuppressive tumor microenvironments and optimize anti-PD-1 immunotherapy for different GBM subtypes. Our clinical and experimental analyses demonstrated that molecularly distinct GBM subtypes have distinct epigenetic and immune signatures that may lead to different immunosuppressive mechanisms. The real-time analysis in GBM-on-a-Chip showed that mesenchymal GBM niche attracted low number of allogeneic CD154+CD8+ T-cells but abundant CD163+ tumor-associated macrophages (TAMs), and expressed elevated PD-1/PD-L1 immune checkpoints and TGF-β1, IL-10, and CSF-1 cytokines compared to proneural GBM. To enhance PD-1 inhibitor nivolumab efficacy, we co-administered a CSF-1R inhibitor BLZ945 to ablate CD163+ M2-TAMs and strengthened CD154+CD8+ T-cell functionality and GBM apoptosis on-chip. Our ex vivo patient-specific GBM-on-a-Chip provides an avenue for a personalized screening of immunotherapies for GBM patients.more » « less
-
Zhang, Rui; Stanley, Natalie; Griggs, Christopher; Chi, Andrew; Sturton, Cynthia (, Proceedings of the Twenty-Second International Conference on Architectural Support for Programming Languages and Operating Systems)We present a methodology for identifying security critical properties for use in the dynamic verification of a processor. Such verification has been shown to be an effective way to prevent exploits of vulnerabilities in the processor, given a meaningful set of security properties. We use known processor errata to establish an initial set of security-critical invariants of the processor. We then use machine learning to infer an additional set of invariants that are not tied to any particular, known vulnerability, yet are critical to security. We build a tool chain implementing the approach and evaluate it for the open-source OR1200 RISC processor. We find that our tool can identify 19 (86.4%) of the 22 manually crafted security-critical properties from prior work and generates 3 new security properties not covered in prior work.more » « less
An official website of the United States government
